12,502 Shares in Fulgent Genetics, Inc. (NASDAQ:FLGT) Bought by Intech Investment Management LLC

Intech Investment Management LLC bought a new position in Fulgent Genetics, Inc. (NASDAQ:FLGT) in the third quarter, HoldingsChannel.com reports. The firm bought 12,502 shares of the company’s stock, valued at approximately $272,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its stake in Fulgent Genetics by 0.9% in the 2nd quarter. Rhumbline Advisers now owns 68,210 shares of the company’s stock worth $1,338,000 after purchasing an additional 637 shares during the period. Signaturefd LLC boosted its stake in Fulgent Genetics by 103.6% in the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock worth $44,000 after purchasing an additional 1,132 shares during the period. Marquette Asset Management LLC boosted its stake in Fulgent Genetics by 13.7% in the 3rd quarter. Marquette Asset Management LLC now owns 9,908 shares of the company’s stock worth $215,000 after purchasing an additional 1,191 shares during the period. Asset Dedication LLC acquired a new position in Fulgent Genetics in the 2nd quarter worth $33,000. Finally, nVerses Capital LLC acquired a new position in Fulgent Genetics in the 2nd quarter worth $43,000. 48.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently commented on FLGT shares. Piper Sandler reduced their price objective on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research note on Monday, November 11th. StockNews.com downgraded shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 27th.

Fulgent Genetics Stock Performance

Shares of FLGT stock opened at $20.20 on Thursday. The firm’s 50-day moving average is $19.69 and its 200-day moving average is $21.05. The stock has a market cap of $617.86 million, a price-to-earnings ratio of -3.66 and a beta of 1.42. Fulgent Genetics, Inc. has a 52-week low of $16.56 and a 52-week high of $30.68.

Insider Activity

In other news, CEO Ming Hsieh sold 2,227 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $18.26, for a total value of $40,665.02. Following the sale, the chief executive officer now directly owns 703,711 shares of the company’s stock, valued at approximately $12,849,762.86. This represents a 0.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have sold 3,413 shares of company stock valued at $62,321. 32.66% of the stock is owned by company insiders.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.